Randomized trial finds drug therapy reduces hot flashes during prostate cancer treatment

Randomized trial finds drug therapy reduces hot flashes during prostate cancer treatment

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer. This primary analysis of Alliance A222001 is published in the Journal of Clinical Oncology.

Randomized Trial Reveals Effective Drug Therapy for Reducing Hot Flashes in

In a groundbreaking clinical trial that could reshape supportive care in prostate cancer treatment, researchers from the Alliance for Clinical Trials in Oncology have demonstrated that oxybutynin, an antimuscarinic agent traditionally employed to manage overactive bladder symptoms, significantly mitigates hot flashes in men undergoing androgen-deprivation therapy (ADT). Published in the Journal of Clinical Oncology, the study rigorously evaluate…